Tidal Investments LLC Has $47.48 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Tidal Investments increased its Pfizer position by 2.4% in the second quarter, adding 46,450 shares to own 1,971,885 shares valued at approximately $47.48 million.
• Pfizer’s latest quarterly results beat expectations, with adjusted EPS of $0.77 versus $0.68 expected and revenue of $15.03 billion versus $14.40 billion forecast. Management maintained full-year 2026 EPS guidance of $2.80–$3.00.
• Despite a 6.2% dividend yield, analyst sentiment remains cautious: Pfizer has a consensus “Hold” rating and an average price target of $28.28, while institutional investors collectively own 68.36% of its shares.

Tidal Investments LLC increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 2.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,971,885 shares of the biopharmaceutical company's stock after acquiring an additional 46,450 shares during the period. Tidal Investments LLC's holdings in Pfizer were worth $47,483,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Handelsbanken Fonder AB raised its position in shares of Pfizer by 10.4% in the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company's stock valued at $59,295,000 after purchasing an additional 232,528 shares during the period. Russell Investments Group Ltd. grew its stake in Pfizer by 15.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company's stock valued at $132,365,000 after buying an additional 745,213 shares during the last quarter. Leuthold Group LLC bought a new position in Pfizer in the 2nd quarter worth $4,887,000. North Dakota State Investment Board acquired a new position in Pfizer during the 4th quarter worth $5,348,000. Finally, Park National Corp OH boosted its holdings in Pfizer by 332.1% during the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company's stock valued at $5,829,000 after acquiring an additional 186,053 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s latest quarterly results exceeded expectations, with adjusted earnings of $0.77 per share versus the $0.68 consensus and revenue of $15.03 billion versus estimates of $14.40 billion. The results helped revive the stock after a prolonged downturn and reinforced management’s full-year 2026 EPS guidance of $2.80-$3.00. Why Pfizer Stock Was so Healthy in August
• Positive Sentiment: Analysts point to Pfizer’s non-COVID portfolio, oncology pipeline and cost-cutting initiatives as potential growth and margin supports. These factors could help offset falling COVID product sales and extend the company’s recovery. Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
• Neutral Sentiment: Pfizer will present at the Morgan Stanley Global Healthcare Conference on September 14. Chief Executive Albert Bourla’s comments could provide updates on the pipeline, capital allocation and the company’s strategy for managing patent losses. Pfizer Invites Public to Listen to Webcast
• Neutral Sentiment: Novartis India agreed to acquire Pfizer brands for $132 million, including an established hypertension product. The transaction may generate cash and streamline Pfizer’s portfolio, but its financial impact appears limited relative to Pfizer’s roughly $159 billion market value. Novartis India Acquires Pfizer Brands
• Negative Sentiment: Jim Cramer selected Johnson & Johnson over Pfizer among healthcare stocks, a high-profile preference that may weigh on Pfizer’s relative appeal. Another comparison favored AbbVie as a stronger dividend-growth investment, despite Pfizer’s roughly 6% yield. Jim Cramer Picks J&J Over Pfizer

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. dropped their price objective on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 8th. Guggenheim lowered their target price on Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a report on Friday, August 7th. Bank of America dropped their price target on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. Wolfe Research reissued an "underperform" rating and issued a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Finally, HSBC downgraded shares of Pfizer from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus price target of $28.28.

Pfizer Stock Up 0.1%

PFE stock opened at $27.82 on Thursday. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $29.21. The company has a market cap of $158.58 billion, a PE ratio of 36.61, a price-to-earnings-growth ratio of 1.87 and a beta of 0.34. The business's 50-day simple moving average is $26.21 and its 200 day simple moving average is $26.35. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the firm posted $0.78 EPS. The company's revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer's payout ratio is currently 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.